In case you havn't yet read this, it's worth a little glanceInventors:Gage, Peter William (Via Queanbeyan, AU)
Ewart, Gary Dinneen (Hackett, AU)
Wilson, Lauren Elizabeth (Ainslie, AU)
Best, Wayne (Gosnells, AU)
Premkumar, Anita (Nicholls, AU)Application Number:16/554990Publication Date:12/26/2019Filing Date:08/29/2019View Patent Images:Export Citation:Assignee:Biotron Limited (Sydney, AU)International Classes:C07D241/34; A61K31/00; A61K31/165; A61K31/4965; A61K31/55; A61K45/06; C07C279/22; A61KPrimary Examiner:CHANDRAKUMAR, NIZAL SAttorney, Agent or Firm:AMSTER, ROTHSTEIN & EBENSTEIN LLP (90 PARK AVENUE, NEW YORK, NY, 10016, US)SUMMARY OF THE INVENTION
The inventors have surprisingly found that certain compounds that fall under the classification of substituted acylguanidines have antiviral activity against viruses from a range of different virus families. Without intending to be bound by any particular theory or mechanism of action, and despite current dogma, it appears possible that viral replication can be retarded by inhibiting or otherwise down-regulating the activity of ion channels expressed in the host cell. Thus, the negative impact of the compounds of the present invention on viral replication may be mediated by the inhibition or otherwise down-regulation of a membrane ion channel relied upon by the virus for replication. This membrane ion channel may be a viral membrane ion channel (exogenous to the host cell) or a host cell ion channel induced as a result of viral infection (endogenous to the host cell).
As an example, the compounds of the present invention may inhibit Vpu or p7 function and thereby inhibit the continuation of the respective HIV or HCV life cycle.
The SARS virus encodes an E protein which is shown for the first time, by the present inventors, to act as an ion channel. As similar E proteins are present in other coronaviruses, the compounds, compositions and methods of the present invention would have utility in the inhibition and/or treatment of infections by other coronaviruses.
